Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00909545 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease
A Phase 2 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 2
- Development phase
- 99
- Enrollment target
NCT00909545 is a Phase 2 study that has completed, run by Northwestern University. The registered enrollment target is 99 participants.
The verdict
NCT00909545, a Phase 2 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 99 participants
- Enrollment target
Study Summary
The primary purpose of this study is to establish a dosage of isradipine CR that is tolerable and demonstrates preliminary efficacy for utilization in future pivotal efficacy studies.
Interventions
- DRUG Placebo
- DRUG Isradipine CR 5mg
- DRUG Isradipine CR 10mg
- DRUG Isradipine CR 20mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 99 participants |
| Start Date | 2009-07 |
| Est. Completion | 2012-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00909545
The ClinicalTrials.gov registry entry for NCT00909545 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00909545 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00909545 about?
NCT00909545 is a clinical study titled "Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease". The primary purpose of this study is to establish a dosage of isradipine CR that is tolerable and demonstrates preliminary efficacy for utilization in future pivotal efficacy studies.
What is the current status of trial NCT00909545?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 99 participants. The study started on 2009-07. Estimated completion is 2012-02.
What interventions are being tested in trial NCT00909545?
The interventions under investigation include: Placebo (DRUG), Isradipine CR 5mg (DRUG), Isradipine CR 10mg (DRUG), Isradipine CR 20mg (DRUG).
Who is sponsoring clinical trial NCT00909545?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.